Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
51 hedge funds and large institutions have $118M invested in Inozyme Pharma in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 9 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
0.69% less ownership
Funds ownership: 73.9% → 73.21% (-0.69%)
2% less funds holding
Funds holding: 52 → 51 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
42% less capital invested
Capital invested by funds: $203M → $118M (-$84.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$2.01M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.13M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$1.08M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$669K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$586K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.23M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$1.34M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.06M |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$762K |
| 5 |
BlackRock
New York
|
-$550K |
INZY Hedge Fund Activity: Q4 2021 in Review
51 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2021, worth a combined $118M — down 42% from $203M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of INZY and 8 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 17 added.
The largest buyer was OrbiMed, adding an estimated $2.01M. The largest seller was Wellington Management Group, exiting entirely with an estimated $4.23M sold.
- 51 institutional investors held Inozyme Pharma (INZY) as of Q4 2021, down from 52 in Q3 2021.
- Funds reported $118M of Inozyme Pharma stock for Q4 2021, down 42% quarter-over-quarter.
- 8 funds opened new Inozyme Pharma positions in Q4 2021 and 9 closed out, a net change of -1 holder.
- The largest Inozyme Pharma buyer in Q4 2021 was OrbiMed, an estimated $2.01M added.
- The largest Inozyme Pharma seller in Q4 2021 was Wellington Management Group, an estimated $4.23M sold.
Based on aggregated 13F filings for Q4 2021.